GCs comment on the Hungarian pharmaceuticals industry

The pharmaceutical market in Emerging Europe is clearly facing a need for realignment with pressing issues of reduced health care expenditure, governmental cost reductions, product pricing, generics and the list goes on and on. This issue of 'On the GC Grapevine' talks to general counsels from a number of prominent players in the pharmaceuticals industry to ask: How is Hungary’s Pharma industry planning to endure the next 5, 10 years and beyond? What are the major influencing factors in Hungary at present and what is everyone debating? Will innovation suffer? The interviews cover a range of topics including the issues around generic drugs, price competition and changing governmental policies.

GCs comment on the Hungarian pharmaceuticals industry issuu.com Mon, Nov 21, 2011